Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 5/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.37 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 3/20 | 0.35 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14045202 | 0.79 | SCN8A (0.36) | MAPK14SCN8ASCN10AHSPB1CGAS | |
| SCHEMBL21104547 | 0.78 | ALDH1A1 (0.52) | MAPK14HSPB1MEN1ALDH1A1MAPT | |
| SCHEMBL4783365 | 0.77 | HSPB1 (0.58) | HSPB1MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL3179628 | 0.77 | ALDH1A1 (0.56) | MEN1ALDH1A1MAPTKMT2APARP10 | |
| SCHEMBL3024118 | 0.75 | HSPB1 (0.50) | MAPK14HSPB1MEN1ALDH1A1MAPT | |
| SCHEMBL31287801 | 0.75 | HSPB1 (0.50) | MAPK14HSPB1MEN1ALDH1A1MAPT | |
| SCHEMBL25968454 | 0.74 | MEN1 (0.40) | MAPK14HSPB1BRD4MEN1ALDH1A1 | |
| SCHEMBL30059265 | 0.74 | MEN1 (0.40) | MAPK14HSPB1BRD4MEN1ALDH1A1 | |
| SCHEMBL22069681 | 0.72 | MAPT (0.57) | MAPK14HSPB1MEN1ALDH1A1MAPT | |
| SCHEMBL15891168 | 0.72 | HSPB1 (0.41) | MAPK14HSPB1MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| WO-2008046216-A1 | KINASE INHIBITORS AND USES THEREOF | METHYLGENE, INC. (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | MAPK14 209/4885SCN8A 4774/4885SCN10A 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.